StockNews.AI

Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds

StockNews.AI • 37 minutes

MCKBMY
High Materiality7/10

Information

LITTLETON, Colo., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Compan...

Original source

AI Summary

Vivos Therapeutics exercised warrants for 1,982,356 shares at $2.34 each. Gross proceeds from the warrant exercise are expected to be $4.64 million. The new warrants allow purchase of additional 3,964,712 shares at $2.09 each. Vivos plans to use proceeds for working capital and corporate purposes. Offering expected to close by January 20, 2026.

Sentiment Rationale

The significant capital raised will bolster operational stability and growth potential, similar to past dilution-neutral events in biotech.

Trading Thesis

Immediate capital from warrant exercise enhances liquidity; effects should be observed quickly.

Market-Moving

  • Vivos Therapeutics exercised warrants for 1,982,356 shares at $2.34 each.
  • Gross proceeds from the warrant exercise are expected to be $4.64 million.
  • The new warrants allow purchase of additional 3,964,712 shares at $2.09 each.

Key Facts

  • Vivos Therapeutics exercised warrants for 1,982,356 shares at $2.34 each.
  • Gross proceeds from the warrant exercise are expected to be $4.64 million.
  • The new warrants allow purchase of additional 3,964,712 shares at $2.09 each.
  • Vivos plans to use proceeds for working capital and corporate purposes.
  • Offering expected to close by January 20, 2026.

Companies Mentioned

  • MCK (MCK)
  • BMY (BMY)

Corporate Developments

The warrant exercise increases liquidity and market confidence, enhancing investor sentiment.

Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million in Gross Proceeds

Date: January 16, 2026 | Source: GlobeNewsWire

Overview of the Announcement

LITTLETON, Colo., January 16, 2026 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (NASDAQ: VVOS), a pioneer in the medical device and healthcare services sector specializing in sleep-related breathing disorders, today disclosed that it has entered a definitive agreement for the immediate exercise of certain outstanding warrants. This agreement enables the purchase of up to 1,982,356 shares of common stock at reduced exercise prices, generating approximately $4.64 million in gross proceeds.

Details of the Warrant Exercise

The warrants in question were initially issued in January 2023, November 2023, and February 2024. The exercise prices range from $3.83 to $5.05 per share, but will now be exercised at a lower price of $2.34 per share. The shares available through this exercise are registered for resale under a Form S-3 registration statement (Registration No. 333-278564).

  • Gross Proceeds: Approximately $4.64 million (pre-expense)
  • Placement Agent: H.C. Wainwright & Co.
  • New Warrants: 3,964,712 shares at an exercise price of $2.09

Implications for Vivos Therapeutics

The new warrants will be issued in a private placement and will be immediately exercisable upon issuance. The initial set of warrants allowing for 1,982,356 shares will expire five years after issuance, while the remaining warrants will expire in twenty-four months.

The expected closing date for this offering is around January 20, 2026, contingent upon standard closing conditions. The net proceeds from this exercise will primarily be allocated for working capital and general corporate purposes.

About Vivos Therapeutics

Founded in 2016 and headquartered in Littleton, Colorado, Vivos Therapeutics, Inc. (NASDAQ: VVOS) focuses on innovative diagnostic and treatment methods for patients affected by obstructive sleep apnea (OSA) and other related conditions. The company’s products, including their Complete Airway Repositioning and Expansion (CARE) devices, are FDA-cleared for treating OSA in both adults and children.

Despite its prevalence, with over 1 billion individuals globally affected by OSA, approximately 90% remain undiagnosed. Vivos aims to address this gap by offering effective, non-invasive solutions tailored to patients' needs.

Forward-Looking Statements

This announcement contains forward-looking statements, including but not limited to the completion of the offering and intended uses of the proceeds. These statements involve risks and uncertainties and may materially differ from actual results as they rely on various scenarios and assumptions. For a comprehensive understanding of potential risks, please refer to Vivos’ filings with the Securities and Exchange Commission (SEC).

Related News